This study employs a cluster randomization design to examine the vaccine effectiveness of Flublok relative to that of other flu vaccines used at Kaiser Permanente Northern California over two influenza seasons (2018 to 2019 and 2019 to 2020), in Kaiser Pe...
Funder: Protein Sciences Corporation
Investigator: Klein, Nicola
|
The purpose of this project is, first, to estimate the proportion of the population under study receiving one and two doses of recombinant zoster vaccine (RZV). Second, among live zoster vaccine (ZVL)-naive persons, this study aims to: 1) estimate the...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
This project will estimate Prevnar 13 (PCV13) vaccine effectiveness against invasive pneumococcal disease using a test-negative design in the Kaiser Permanente Northern California adult population from September 1, 2014, through December 31, 2017. Positiv...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study has three primary aims: 1) to estimate the relative vaccine effectiveness of Flucelvax versus inactivated influenza vaccine (IIV) in vaccinated Kaiser Permanente Northern California members aged 4 to 64 years against all PCR-confirmed influ...
Funder: Shoo the Flu, LLC
Investigator: Klein, Nicola
|
Funder: ICON Clinical Research PLC
Investigator: Klein, Nicola
|
This is a phase IIIB, observer-blind, randomized, placebo-controlled, multi-center study to assess the safety and immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when administered concomitantly with routine vaccines ...
Funder: GlaxoSmithKline PLC
Investigator: Klein, Nicola
|
This project will identify all patients who have a laboratory-confirmed diagnosis of Hepatitis C. The intervention group will be those who had a prescription filled for a new antiviral medication after October 10, 2014, and who were naive to treatment for...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
Although the benefits of combination antiretroviral therapy (ART) for reducing HIV-related morbidity and mortality are well-recognized, toxicity from some ART may potentially contribute to excess age-related comorbidities. Certain antiretrovirals, includi...
Funder: Gilead Sciences, Inc.
Investigator: Silverberg, Michael
|
This project will identify all patients who have a laboratory-confirmed diagnosis of Hepatitis C. The intervention group will be those who had a prescription filled for a new antiviral medication after October 10, 2014, and who were naive to treatment for...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
This project has three major aims: 1) to examine whether influenza vaccination during pregnancy prevents influenza and other respiratory infections in infants aged 0 to 12 months, with a sub-aim to examine the effect of vaccine timing during pregnancy...
Funder: National Institute of Allergy and Infectious Diseases
Investigator: Zerbo, Ousseny
|
Kaiser Permanente Northern California has recently collaborated with Pfizer in identifying invasive and noninvasive group B streptococcus (GBS) disease burden in adults during a seven-year time period spanning 2007 to 2014. In Phase 1 of this research col...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
This study will investigate the safety of direct-acting antiviral medications in patients who have a laboratory-confirmed diagnosis of hepatitis C. The intervention group will be those who had a prescription filled for a new antiviral medication after Oct...
Funder: Patient-Centered Outcomes Research Institute
Investigator: Silverberg, Michael
|
The goal of this project is to determine the age-specific rates of laboratory-confirmed influenza-associated hospitalization among children, and to describe clinical and epidemiologic characteristics of pediatric hospitalized case-patients during the infl...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
The three objectives of this study are to: 1) Identify and compare the clinical, demographic and neighborhood characteristics associated with receipt of pneumococcal vaccine among persons 65 years of age and older, and among persons 18 to 64 years of ...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
With support from the National Institute on Alcohol Abuse and Alcoholism, the Consortium to improve OutcoMes in HIV/Aids, Alcohol, Aging & multi-Substance (COMpAAAS) has analyzed data from patients in the Veterans Administration Cohort Study. This pro...
Funder: National Institute on Alcohol Abuse and Alcoholism
Investigator: Satre, Derek; Silverberg, Michael
|
This study is a phase 3, randomized, active-controlled, observer-blinded study to assess the immunogenicity, safety, and tolerability of bivalent rLP2086 when administered as a two-dose regimen in healthy subjects 10 to 26 years of age. The project also i...
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
The hub server is used to transfer programs and related files to Vaccine Safety Datalink (VSD) sites from the Centers for Disease Control and Prevention (CDC), and to transfer output from these programs back to CDC. The hub provides a common point that ca...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
The purpose of this project is to provide the Centers for Disease Control and Prevention (CDC) Immunization Safety Office with an as-needed mechanism to obtain required services through the issuance of individual task orders in support of vaccine safety m...
Funder: Centers for Disease Control and Prevention
Investigator: Klein, Nicola
|
Lung cancer is now a leading cause of death in HIV infected persons. Lung cancer survival is worse in HIV infected persons, in part due to uncertainty regarding the optimal treatment pathways for this group. In this project we will use data from several l...
Funder: National Cancer Institute
Investigator: Silverberg, Michael
|
A phase IIIA, randomized, single-blind, multi-centric study to evaluate the immunogenicity, reactogenicity and safety of three doses of Pediarix, Hiberix and Prevenar 13 when co-administered with two doses of the PCV-free liquid formulation of GSK Biologi...
Funder: GlaxoSmithKline PLC
Investigator: Klein, Nicola
|
The aims of this study are: 1) To determine genetic factors and immunologic patterns that may predict the occurrence of fever after measles vaccines by analyzing previously collected biospecimens during a randomized controlled MMR clinical trial. 2) T...
Funder: Office of the Assistant Secretary for Health
Investigator: Klein, Nicola
|
This a cohort study of KPNC patients initiating interferon-free treatment for HCV infection, with the following specific aims: 1) Determine the short- and long-term effectiveness of interferon-free treatment for HCV infection, 2) determine the safety ...
Funder: The Permanente Medical Group
Investigator: Silverberg, Michael
|
A prospective, epidemiological, interventional, multi-country based, cohort study to assess the disease burden of respiratory syncytial virus (RSV) associated, suspected lower respiratory tract infections (LRTIs) in newborns, etc.
Funder:
Investigator: Klein, Nicola
|
The objective of this study is to develop methods to accurately predict cardiovascular disease (CVD) risk for HIV patients. CVD risk is increased for HIV patients, yet accurate methods for risk prediction remain unclear. We will evaluate the performance o...
Funder: National Heart, Lung, and Blood Institute
Investigator: Silverberg, Michael
|
Pfizer’s investigational Clostridium difficile vaccine (PF-06425090) is a prophylactic vaccine that is currently being investigated for the prevention of primary C difficile infection in adults 50 years of age and older.
Funder: Pfizer Inc.
Investigator: Klein, Nicola
|
|
